1. Home
  2. RBOT vs SKYE Comparison

RBOT vs SKYE Comparison

Compare RBOT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RBOT
  • SKYE
  • Stock Information
  • Founded
  • RBOT 2014
  • SKYE 2012
  • Country
  • RBOT United States
  • SKYE United States
  • Employees
  • RBOT N/A
  • SKYE N/A
  • Industry
  • RBOT Medical Specialities
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • RBOT Health Care
  • SKYE Health Care
  • Exchange
  • RBOT Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • RBOT 86.1M
  • SKYE 80.7M
  • IPO Year
  • RBOT N/A
  • SKYE N/A
  • Fundamental
  • Price
  • RBOT $15.00
  • SKYE $3.16
  • Analyst Decision
  • RBOT Hold
  • SKYE Buy
  • Analyst Count
  • RBOT 2
  • SKYE 6
  • Target Price
  • RBOT $10.25
  • SKYE $18.67
  • AVG Volume (30 Days)
  • RBOT 38.5K
  • SKYE 213.2K
  • Earning Date
  • RBOT 03-03-2025
  • SKYE 02-18-2025
  • Dividend Yield
  • RBOT N/A
  • SKYE N/A
  • EPS Growth
  • RBOT N/A
  • SKYE N/A
  • EPS
  • RBOT N/A
  • SKYE N/A
  • Revenue
  • RBOT N/A
  • SKYE N/A
  • Revenue This Year
  • RBOT N/A
  • SKYE N/A
  • Revenue Next Year
  • RBOT N/A
  • SKYE N/A
  • P/E Ratio
  • RBOT N/A
  • SKYE N/A
  • Revenue Growth
  • RBOT N/A
  • SKYE N/A
  • 52 Week Low
  • RBOT $4.27
  • SKYE $2.31
  • 52 Week High
  • RBOT $19.00
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • RBOT 58.49
  • SKYE 52.61
  • Support Level
  • RBOT $11.73
  • SKYE $2.60
  • Resistance Level
  • RBOT $13.92
  • SKYE $3.54
  • Average True Range (ATR)
  • RBOT 1.06
  • SKYE 0.48
  • MACD
  • RBOT 0.10
  • SKYE 0.03
  • Stochastic Oscillator
  • RBOT 93.70
  • SKYE 34.73

About RBOT Vicarious Surgical Inc.

Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: